Greg Bell, Andrew Tepperman, and Justin Ho co-authored a chapter in the ninth edition of The Investment Treaty Arbitration Review. The chapter titled “Investment Treaty Disputes in the Life Sciences Industry” addresses the features and incentives of the life sciences industry as they lead to tensions and disputes between governments and companies. The chapter further discusses valuation considerations for practitioners and future issues arising from current developments in the life sciences industry.
Articles
Life sciences considerations for investment treaty disputes
August 26, 2024
Key contacts
![Gregory Bell | Expert Witness | Charles River Associates]()
Gregory K. BellGroup Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.com![Andrew Tepperman | Life Sciences Litigation | Charles River Associates]()
![]()
Upcoming events
Asembia’s AXS26 Summit
CRA is a proud supporter of the conference where attendees span the full spectrum of the pharmacy and healthcare ecosystem, bringing together key...
GAR Live: Life Sciences
CRA is a proud sponsor of the first-ever GAR Live: Life Sciences, evolving from the much-loved Technology Disputes event to reflect the growing complexity and...